Hairy Cell Leukemia Market

Market Overview:

The 7 major hairy cell leukemia markets reached a value of US$ 42.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 63.6 Million by 2034, exhibiting a growth rate (CAGR) of 3.84% during 2024-2034.

The hairy cell leukemia market has been comprehensively analyzed in IMARC's new report titled "Hairy Cell Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hairy cell leukemia is a rare type of cancer that affects the blood and bone marrow. In this condition, the abnormal B cells (hairy cells) do not function properly and accumulate in the bone marrow, crowding out normal blood cells. These hairy cells have a characteristic appearance under the microscope, with fine hair-like projections on their surface. Individuals suffering from the ailment may experience a feeling of fullness in the belly, fatigue, easy bruising, recurring infections, weakness, enlarged spleen, unexplained weight loss, etc. The other common symptoms of this disease include night sweat, fever, shortness of breath, and painless lumps in the neck, groin, underarm, or stomach. The diagnosis of hairy cell leukemia is based on a review of the patient's medical history, clinical features, and physical exam. The healthcare provider may perform various diagnostic procedures and tests, such as peripheral blood smear, complete blood count (CBC), computed tomography (CT) scan, flow cytometry, bone marrow aspiration and biopsy, etc., among patients to validate the exact cause of the underlying indications.

The increasing cases of genetic conditions on account of gene mutations, DNA abnormalities, chromosomal changes, etc., are primarily driving the hairy cell leukemia market. In addition to this, the rising incidence of several associated risk factors, including advanced age, family history, exposure to certain chemicals and toxins, etc., is further creating a positive outlook for the market. Moreover, the widespread adoption of recombinant interferon alpha-2b for treating the ailment, since it stops the division of cancer cells and slows tumor proliferation, is also bolstering the market growth. Additionally, numerous key players are investing in R&D activities to launch effective novel therapies with higher bioavailability, lesser side effects, and improved gastrointestinal absorption. This, in turn, is acting as a significant growth-inducing factor. Furthermore, the emerging popularity of targeted therapies, involving vemurafenib and ibrutinib, which block specific proteins made by the mutated BRAF gene and prevent cancer cells from growing, is expected to drive the hairy cell leukemia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the hairy cell leukemia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for hairy cell leukemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hairy cell leukemia market in any manner.

Key Highlights:

• Hairy cell leukemia represents fewer than 2% of all leukemias.
• The incidence of the disease is 0.3 cases per 100,000 persons.
• According to the National Organization for Rare Disorders (NORD), approximately 6,000 Americans have hairy cell leukemia.
• The median age at diagnosis was 58 years, with an average male-to-female ratio of 1.5-2:1.
• The incidence is around three times higher in White than in Black people.

Drugs:

Cladribine is a first- and second-line treatment for symptomatic hairy cell leukemia, delivered intravenously or subcutaneously. Cladribine is absorbed by nucleoside transporter proteins.

Brexucabtagene autoleucel (previously KTE X19) is a chimeric antigen receptor T cell (CAR T) treatment developed by Kite Pharma. It is formulated as a suspension for intravenous delivery. The medicine is a CD19-directed genetically modified autologous T cell immunotherapy made up of the patient's T cells that are extracted and genetically changed ex vivo using retroviral transduction.

Elranatamab is an experimental, off-the-shelf, humanized BCMA CD3-targeting BsAb. BsAbs are a new type of cancer immunotherapy that binds to and activates two distinct targets at once. One arm bind directly to specific antigens on cancer cells, while the other connects to T-cells, bringing the two cell types together. Elranatamab's binding affinity for BCMA and CD3 has been designed to produce strong T-cell-mediated anti-myeloma action. Elranatamab is delivered subcutaneously, which is more convenient than intravenous administration.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hairy cell leukemia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hairy cell leukemia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current hairy cell leukemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the hairy cell leukemia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the hairy cell leukemia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the hairy cell leukemia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of hairy cell leukemia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of hairy cell leukemia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of hairy cell leukemia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with hairy cell leukemia across the seven major markets?
• What is the size of the hairy cell leukemia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of hairy cell leukemia?
• What will be the growth rate of patients across the seven major markets?
   

Hairy Cell Leukemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for hairy cell leukemia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hairy cell leukemia market?
• What are the key regulatory events related to the hairy cell leukemia market?
• What is the structure of clinical trial landscape by status related to the hairy cell leukemia market?
• What is the structure of clinical trial landscape by phase related to the hairy cell leukemia market?
• What is the structure of clinical trial landscape by route of administration related to the hairy cell leukemia market?